

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 05-252-G)

P	Δ	T	E	N	T
1.	$\boldsymbol{\Box}$		Ľ.	1.4	

In app	olication of:	)	
	Gaston et al.	) Before the Examination	nor•
	Guston et ut.	,	
		) R. Henley	Ш
Serial	No. 10/772,374	)	
		) Group Art Unit:	
Filed:	February 6, 2004	) 1614	
For:	Therapeutic Use of Aerosolized	)	
101.	<del>-</del>	,	
	Nitrosylating Agents in Cystic Fibrosis	)	

Mail Stop Amendment Commissioner for Patents Alexandria, VA 22313-1450

In regard to the above identified application:

- 1. We are transmitting herewith the attached:

  Response to Office Action Mailed August 1, 2005; Return Postcard;
- 2. With respect to fees:
  No fees are required.
- 3. GENERAL AUTHORIZATION TO CHARGE OR CREDIT FEES: Please charge any necessary fees to Deposit Account No. 13-2490.
- 4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as "First Class Mail" in an envelope addressed to: Mail Stop Amendment Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 1<sup>st</sup> day of November 2005.

By:

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff LLP

Dated: November 1, 2005

Jason J. Derry, Ph.D.

Règ No. 50,692



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 05-252-G)

In app	olication of:	)	
		)	
	Gaston et al.	)	Before the Examiner:
		)	R. Henley III
Serial	No. 10/772,374	)	·
•		)	<b>Group Art Unit:</b>
Filed:	February 6, 2004	)	1614
		)	
For:	Therapeutic Use of Aerosolized	)	
	Nitrosylating Agents in Cystic Fibrosis	)	

Mail Stop Amendment Commissioner for Patents Alexandria, VA 22313-1450

## **RESPONSE TO OFFICE ACTION MAILED AUGUST 1, 2005**

Dear Sir:

Responsive to the Office Action, mailed August 1, 2005, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

Amendments to the Claims begin on page 2.

Amendments to the Specification begin on page 3.

Remarks begin on page 4.